Company intelligence / Profile preview

Cortene Inc.

Burlingame, California, United Statescorteneinc.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Completed a Phase 2 proof-of-concept clinical trial (InTiME) for ME/CFS using CT38, showing sustained symptom improvement. At an infusion rate of 0.03 μg/kg/h, mean total daily symptom score improved by 26% (p < 0.01, n = 7). The company is planning trials for Parkinson's and Alzheimer's.

Therapeutic areas: NephrologyImmunologyNeurologyInfectious Diseases
Modalities: Peptide-based treatments
Industry: Biotech

Drug pipeline

1 asset

CT38

Partnerships

Bateman Horne Center (for clinical trials)

Beyond the preview

Go deeper on Cortene Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cortene Inc..

Explore the full profile